drugset / Trial / NCT01565330

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

NCT01565330

Phase 1 Completed 20 enrolled Avid Radiopharmaceuticals
Non-randomizedParallel-groupSingle-blindDiagnostic

Summary

This study will test two different doses of florbetapir F 18 to determine which dose is best to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron emission tomography (PET) scanner.

Timeline

Start
2008-03
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject florbetapir F 18 Diagnostic / imaging agent 111 mbq Intravenous
Subject florbetapir F 18 Diagnostic / imaging agent 370 mbq Intravenous

Indications